Role of free radical oxidation, hypoxia and their correction in COVID-19 pathogenesis

This article is in "Library" section.

Author:

A.V. SCHULKIN, A.A. FILIMONOVA
Academician I.P. Pavlov Ryazan State Medical University of the Ministry of Healthcare of Russia

Read more.


Antioxidants/antihypoxants: the missing puzzle piece in effective pathogenetic therapy for COVID-19

This article is in "Library" section.

Author:

T.A. VORONINA
V.V.Zakusov Research Institute of Pharmacology, Moscow, Russian Federation

Read more.


The role of oxidative stress in the development of vascular cognitive disorders

This article is in "Library" section.

Author:

A.N. BOGOLEPOVA
Pirogov Russian National Research Medical University, Moscow, Russia;
Federal Center of Brain Research and Neurotechnologies, Moscow, Russia

Read more.


Mexidol® and Mexidol® FORTE 250 in consecutive therapy of cognitive disorders in comorbid patients with joint pathology on the background of arterial hypertension and ischemic heart disease

This article is in "Library" section.

Author:

L.N. ELISEEVA, S.V. KARTASHOVA
Kuban State Medical University of the Ministry of Healthcare of Russia, Krasnodar

Read more.


The theses of the study confirming the antioxidant properties of Mexidol® are accepted by the European Society of Cardiology (ESC)

The results of the study of the effect of Mexidol® (2-ethyl-6-methyl-3-hydroxypyridine succinate) on oxidative stress in patients with decompensated heart failure and cognitive impairment are published on the website of the European Society of Cardiology, https://www.escardio.org/Search/?q=Mexidol&filters:content_type=ESC365%20Presentation. The purpose of the study was to evaluate the effect of Mexidol® on the level of oxidative stress markers (malondialdehyde*, superoxide dismutase**, glutathione peroxidase***), plasma antioxidant activity in patients with decompensated heart failure and cognitive impairment. Oxidative stress markers were investigated at the beginning of therapy and after its completion. Patients treated with Mexidol® showed a significant decrease in the level of malondialdehyde - by 20.77% (p=0.02) and a significant increase - by 20.68% - in the level of glutathione peroxidase (p=0.04), as well as a tendency to increase the level of superoxide dismutase by 43.43% and plasma antioxidant activity by 42.69%.

Thus, the study showed a marked antioxidant effect of Mexidol® in patients with decompensated heart failure and cognitive impairment.

Note:

*Malondialdehyde is an endogenous aldehyde, which is a clinical and laboratory oxidative stress marker used to predict and control the treatment of a wide range of diseases, including heart failure.

**Superoxide dismutase is one of the main intracellular antioxidant protection enzymes catalyzing the decomposition of superoxide into oxygen and hydrogen peroxide. It takes an important part in the antioxidant protection of almost all cells.

***Glutathione peroxidase is one of the main intracellular antioxidant enzymes catalyzing restoration of lipid hydroperoxides into alcohols and restoration of hydrogen peroxide to the state of water.


Antioxidants used against viral infections

Escaping coronavirus infection is a question that arises with the awareness of the gravity of the global situation. These are social distance, hand hygiene, and immune system reinforcement that specialists can so far advise. Treatment of pneumonia that develops against the background of COVID-19 infection allows of various clinical and pharmacological approaches, including experimental ones.

One of the directions of respiratory viral infections control may be maintenance of metabolic processes in cells. Using antioxidants, doctors increase the cells protection against oxidative stress and help the cells to resist not only infections, but also heart disease, brain disease and even aging process. Science knows more than 400 types of antioxidants: from ascorbic acid to such antioxidants as Mexidol®, which is included in 38 major standards of medical care in Russia.


The efficacy and safety of Mexidol and Mexidol Forte 250 in patients with chronic cerebral ischemia

This article is in "Library" section.

Author:

Yu.V. ABRAMENKO
Tver State Medical University, Tver, Russia

Read more.


Geroprotective effects of ethylmethylhydroxypyridine succinate in an experimental study

This article is in "Library" section.

Author:

T.A. VORONINA

FSBI «Zakusov Institute of Pharmacology», Moscow

Read more.


The efficacy and safety of ethyl methyl hydroxypyridine succinate used as part of sequential therapy in patients with chronic cerebral ischemia

This article is in "Library" section.

Author:

V.V. BURDAKOV, D.V. KRASNYKH
Orenburg State Medical University, Ministry of Health of Russia, Orenburg, Russia

Read more.


The effect of Mexidol on cerebral mitochondriogenesis at a young age and during aging

This article is in "Library" section.

Author:

YU.I. KIROVA1, F.M. SHAKOVA1, E.L. GERMANOVA1, G.A. ROMANOVA1, T.A. VORONINA2

1 Institute of General Pathology and Pathophysiology, Moscow, Russia;

2 Zakusov Research Institute of Pharmacology, Moscow, Russia

Read more.